QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NASDAQ:MEIP

MEI Pharma - MEIP Stock Forecast, Price & News

$0.50
-0.02 (-3.84%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.49
$0.54
50-Day Range
$0.46
$0.65
52-Week Range
$0.41
$3.55
Volume
788,670 shs
Average Volume
4.04 million shs
Market Capitalization
$66.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.13

MEI Pharma MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
923.0% Upside
$5.13 Price Target
Short Interest
Healthy
4.36% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
0.96mentions of MEI Pharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.69) to ($0.62) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.56 out of 5 stars

Medical Sector

157th out of 1,098 stocks

Pharmaceutical Preparations Industry

59th out of 536 stocks

MEIP stock logo

About MEI Pharma (NASDAQ:MEIP) Stock

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

MEI Pharma Stock Performance

MEI Pharma stock opened at $0.53 on Tuesday. The firm's 50 day moving average price is $0.55 and its two-hundred day moving average price is $0.99. MEI Pharma has a twelve month low of $0.41 and a twelve month high of $3.55.

MEI Pharma (NASDAQ:MEIP - Get Rating) last announced its quarterly earnings data on Monday, May 23rd. The company reported ($0.17) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.17). The company had revenue of $9.69 million during the quarter, compared to analysts' expectations of $6.25 million. MEI Pharma had a negative net margin of 62.40% and a negative return on equity of 71.32%. As a group, sell-side analysts expect that MEI Pharma will post -0.69 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Alliance Global Partners reduced their price target on MEI Pharma from $9.00 to $5.00 in a research report on Wednesday, April 20th. StockNews.com started coverage on MEI Pharma in a report on Thursday, August 4th. They issued a "hold" rating for the company. Finally, BTIG Research cut their price objective on MEI Pharma to $3.00 and set a "na" rating for the company in a research note on Tuesday, May 24th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $5.13.

Receive MEIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MEI Pharma and its competitors with MarketBeat's FREE daily newsletter.

MEIP Stock News Headlines

StockNews.com Begins Coverage on MEI Pharma (NASDAQ:MEIP)
Pacira (PCRX) Q1 Earnings Miss Estimates
Expert Ratings For MEI Pharma
See More Headlines
Receive MEIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MEI Pharma and its competitors with MarketBeat's FREE daily newsletter.

MEIP Company Calendar

Last Earnings
5/23/2022
Today
8/09/2022
Next Earnings (Estimated)
9/01/2022
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MEIP
Previous Symbol
NASDAQ:MSHL
Employees
76
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.13
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+923.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$-41,310,000.00
Pretax Margin
-90.94%

Debt

Sales & Book Value

Annual Sales
$25.53 million
Book Value
$0.44 per share

Miscellaneous

Free Float
125,446,000
Market Cap
$66.63 million
Optionable
Optionable
Beta
0.85

Key Executives

  • Dr. Daniel P. Gold (Age 68)
    Pres, CEO & Director
    Comp: $1.03M
  • Mr. David M. Urso B.A. (Age 58)
    Esq., J.D., COO & Gen. Counsel
    Comp: $680.47k
  • Dr. Robert D. Mass (Age 68)
    Strategic Advisor
    Comp: $201.68k
  • Dr. Richard G. Ghalie (Age 64)
    Chief Medical Officer
    Comp: $550.55k
  • Ms. Virginia Sankey
    VP of Fin.
  • Dr. Eric Deng Ph.D.
    VP of Technical Operations
  • Ms. Tina Clark Beamon Esq.
    J.D., Chief Compliance Officer
  • Mr. Brian T. Powl
    Sr. VP of Marketing
  • Ms. Anne Frese
    Chief People Officer
  • Dr. Karen E. Potts Ph.D. (Age 59)
    Sr. VP of Regulatory Affairs













MEIP Stock - Frequently Asked Questions

Should I buy or sell MEI Pharma stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MEIP shares.
View MEIP analyst ratings
or view top-rated stocks.

What is MEI Pharma's stock price forecast for 2022?

6 brokers have issued 12 month target prices for MEI Pharma's stock. Their MEIP share price forecasts range from $1.00 to $20.00. On average, they anticipate the company's share price to reach $5.13 in the next twelve months. This suggests a possible upside of 935.4% from the stock's current price.
View analysts price targets for MEIP
or view top-rated stocks among Wall Street analysts.

How has MEI Pharma's stock performed in 2022?

MEI Pharma's stock was trading at $2.67 at the start of the year. Since then, MEIP shares have decreased by 81.5% and is now trading at $0.4950.
View the best growth stocks for 2022 here
.

Are investors shorting MEI Pharma?

MEI Pharma saw a drop in short interest during the month of July. As of July 15th, there was short interest totaling 5,800,000 shares, a drop of 19.1% from the June 30th total of 7,170,000 shares. Based on an average daily trading volume, of 4,320,000 shares, the days-to-cover ratio is presently 1.3 days.
View MEI Pharma's Short Interest
.

When is MEI Pharma's next earnings date?

MEI Pharma is scheduled to release its next quarterly earnings announcement on Thursday, September 1st 2022.
View our MEIP earnings forecast
.

How were MEI Pharma's earnings last quarter?

MEI Pharma, Inc. (NASDAQ:MEIP) released its quarterly earnings data on Monday, May, 23rd. The company reported ($0.17) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.17). The business had revenue of $9.69 million for the quarter, compared to analyst estimates of $6.25 million. MEI Pharma had a negative trailing twelve-month return on equity of 71.32% and a negative net margin of 62.40%.

What other stocks do shareholders of MEI Pharma own?

What is MEI Pharma's stock symbol?

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

Who are MEI Pharma's major shareholders?

MEI Pharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Connor Clark & Lunn Investment Management Ltd. (0.06%). Insiders that own company stock include Brian G Drazba, Christine Anna White, Daniel P Phd Gold, Frederick W Driscoll and Thomas C Reynolds.
View institutional ownership trends
.

How do I buy shares of MEI Pharma?

Shares of MEIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MEI Pharma's stock price today?

One share of MEIP stock can currently be purchased for approximately $0.50.

How much money does MEI Pharma make?

MEI Pharma (NASDAQ:MEIP) has a market capitalization of $65.83 million and generates $25.53 million in revenue each year. The company earns $-41,310,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis.

How many employees does MEI Pharma have?

MEI Pharma employs 76 workers across the globe.

How can I contact MEI Pharma?

MEI Pharma's mailing address is 11455 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The official website for the company is www.meipharma.com. The company can be reached via phone at (858) 369-7100, via email at investor@meipharma.com, or via fax at 302-655-5049.

This page (NASDAQ:MEIP) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.